BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics, Inc. - Special Call Transcript

Jan 05, 2021 / 01:30PM GMT
Release Date Price: €41 (-2.84%)
Operator

Hello and welcome to the BioXcel Therapeutics Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I will now turn the call over to BioXcel's CEO, Vimal Mehta. Thank you, sir. Please go ahead.

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Thank you, operator. Good morning, everyone, and thank you for joining our conference call today to discuss our positive top line results from the Phase Ib/II TRANQUILITY trial for the acute treatment of agitation in dementia, including Alzheimer's disease.

This is an exciting day for BioXcel Therapeutics and a hopeful day for dementia patients and their caregivers. As you can imagine from the press release we issued this morning, we are delighted by the findings of the TRANQUILITY study showing that BXCL501 was well tolerated, and demonstrated rapid and durable reductions in agitation in patients with dementia. A copy of the press release is available on BioXcel Therapeutics website. As a reminder, we will be making forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot